Sarah Shigdar
Overview
Explore the profile of Sarah Shigdar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdhury M, Collins J, Gell D, Perry S, Breadmore M, Shigdar S, et al.
ACS Chem Neurosci
. 2023 Dec;
15(2):346-356.
PMID: 38149631
Aptamers are functional oligonucleotide ligands used for the molecular recognition of various targets. The natural characteristics of aptamers make them an excellent alternative to antibodies in diagnostics, therapeutics, and biosensing....
2.
Giles B, Nakhjavani M, Wiesa A, Knight T, Shigdar S, Samarasinghe R
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686652
The key challenges to treating glioblastoma multiforme (GBM) are the heterogeneous and complex nature of the GBM tumour microenvironment (TME) and difficulty of drug delivery across the blood-brain barrier (BBB)....
3.
Thevendran R, Rogini S, Leighton G, Mutombwera A, Shigdar S, Tang T, et al.
Biology (Basel)
. 2023 May;
12(5).
PMID: 37237536
Dengue infection, caused by the dengue virus, is a global threat which requires immediate attention and appropriate disease management. The current diagnosis of dengue infection is largely based on viral...
4.
Nakhjavani M, Shigdar S
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551742
The limited treatment options for triple-negative breast cancer with brain metastasis (TNBC-BM) have left the door of further drug development for these patients wide open. Although immunotherapy via monoclonal antibodies...
5.
Nakhjavani M, Giles B, Strom M, Vi C, Attenborough S, Shigdar S
J Vis Exp
. 2022 Oct;
(187).
PMID: 36190297
A key challenge in developing an anticancer aptamer is to efficiently determine the selectivity and specificity of the developed aptamer to the target protein. Due to its several advantages over...
6.
Henri J, Nakhjavani M, McCoombe S, Shigdar S
Biochimie
. 2022 Sep;
204:108-117.
PMID: 36155804
Despite medical advances in treatment strategies over the past 30-years, epithelial ovarian cancer (EOC) continues to be defined by poor patient survival rates and aggressive, drug resistant relapse. Traditional approaches...
7.
Sarafraz M, Nakhjavani M, Shigdar S, Christo F, Rolfe B
Eur J Pharm Biopharm
. 2022 Mar;
173:121-131.
PMID: 35283304
The blood-brain barrier (BBB) is a strong barrier against the entrance of drugs, which has made brain cancer treatment a major challenge. We have previously shown that targeting transferrin receptors...
8.
Nakhjavani M, Samarasinghe R, Shigdar S
Drug Discov Today
. 2022 Feb;
27(5):1298-1314.
PMID: 35101641
The key challenges with the treatment of triple-negative breast cancer brain metastasis (TNBC-BM) are the lack of any targeted therapy and difficulties associated with drug delivery to the brain. These...
9.
Shigdar S, Agnello L, Fedele M, Camorani S, Cerchia L
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35056924
The identification of tumor cell-specific surface markers is a key step towards personalized cancer medicine, allowing early assessment and accurate diagnosis, and development of efficacious targeted therapies. Despite significant efforts,...
10.
Nakhjavani M, Shigdar S
Pharmacol Res
. 2021 Dec;
175:106019.
PMID: 34861397
Triple-negative breast cancer (TNBC) has the worst prognosis among the subtypes of breast cancer, with no targeted therapy available. Immunotherapy targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1)...